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Hexanucleotide repeat expansions (G4C2) in C9orf72 (chromosome 9 open reading frame 72) are the 
most prevalent genetic cause of frontotemporal dementia and amyotrophic lateral sclerosis [4,8]. 
The normal repeat length is between two and ten units in 90% of the population [8] while 
expansions associated with disease, consist of several hundred or thousands units [2,4]. Expansions 
of between twenty and several hundred units are found in disease and healthy individuals, but the 
size of the smallest expansion unit that confers disease risk is unknown [2,10]. In disease, neuronal 
aggregates are formed, composed of i) sense and anti-sense RNA foci ii) dipeptide repeat proteins 
(DPRs), generated by an unconventional mechanism termed repeat-associated non-ATG (RAN) 
translation and separate TDP43 inclusions [9]. The minimum number of repeats required to generate 
pathology is unknown, but has important implications for understanding disease risk and 
pathogenesis. 
We screened C9orf72 repeat length from the brains of 86 cognitively normal cases from the 
Queen Square Brain Bank. Case 1 demonstrated an expanded pattern up to a 40-unit G4C2 while two 
control cases (cases 2 and 3, aged 75 and 86 respectively) demonstrated a 20-unit G4C2 (Figure 1). A 
sizing PCR of case 1 showed a range of 20-40 repeats with the most abundant peak at 30 repeats. 
The absence of a repeat larger than 40 units in case 1 was confirmed by Southern blotting (figure 1) 
[6].  
Case 1 was cognitively normal with a history of poliomyelitis as a child leaving her with leg 
weakness. Her mobility was also affected by pain attributed to orthopaedic problems. She lived 
alone until she died aged 84 without any cognitive decline.  
No neuropathological abnormalities were found in cases 2 and 3. Macroscopically case 1 
appeared normal (brain weight 1360g). Microscopically there were ‘age-related’ changes with 
neurofibrillary tangle (Braak and Braak stage II) and Aβ plaque pathologies (Thal phase 1). The 
hemispheric white matter showed several foci of recent ischaemic damage. No TDP43-positive 
lesions were present. There were sparse p62-positive inclusions containing all five DPRs, when 
compared with frontotemporal dementia cases with a large C9orf72 repeat expansion 
(supplementary information). The DPRs were present in the hippocampus, cerebellum, frontal and 
temporal cortices (figure 1), but not observed in any other brain regions. Sense and anti-sense RNA 
foci were evident in the frontal cortex (figure 1) but were absent in the hippocampal formation and 
cerebellum. DPR inclusions and RNA foci were absent in both cases with a 20-unit G4C2 repeat, 
suggesting a critical unit repeat length, which may be required to initiate the formation of such 
abnormalities. 
The mechanism of neurodegeneration in C9orf72 expansion cases is unclear. The presence of 
motor dysfunction, defects in endocytosis and autophagy or axonopathy in different models [3,5] 
indicates that loss of C9orf72 function may play a role. Gain of function toxicity by DPRs and/or RNA 
foci is another possible mechanism; both DPRs and RNA foci were present in our case with a 30-unit 
G4C2. All five DPRs being present in our case 1 suggests a threshold DPR length is required for 
toxicity. Pathological studies have also suggested the DPR inclusions may precede the TDP43 
pathology [1,7]. However, the cases reported in these studies contained large C9orf72 expansion 
repeats and were younger than case 1. Unlike in some other neurodegenerative diseases, at present 
no data support the notion that the DPR inclusions observed in our case 1 would be an ‘age-related’ 
phenomenon. Published observations together with those from our case 1 suggest that the 
formation of DPR inclusions may be the earliest event in C9orf72 repeat expansion-related diseases 
[1,7]. It has been shown that wild-type C9orf72 alleles (<20-unit G4C2) are stable between 
generations, whilst, small expansions (20–150-unit G4C2) are susceptible to unfaithful inheritance [2] 
or somatic instability [11]. A recent study reported a paternal ~70-unit G4C2 in C9orf72 expanded and 
passed a large G4C2 expansion (~1,750-unit G4C2) on to four children [12], underpinning the 
significance of small expansions within the normal population, which could potentially be unstable 
and lead to larger expansions in future generations.  
Our data show that C9orf72 disease-specific DPRs produced from a 30-unit G4C2 formed 
characteristic p62-positive inclusions in a cognitively normal case without progressing to TDP43 
pathology, indicating that the 30-unit G4C2 may not be long enough to trigger the entire disease 
cascade and that longer expansion repeats may be necessary to initiate downstream cellular events 
ultimately leading to TDP43 pathology, neurodegeneration and clinical disease.  
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Figure Legend 
Figure 1a-c: Repeat-primed PCR (rp-PCR) from cases 1-3: C9orf72 rp-PCR carried out on DNA 
extracted from the cerebellum. Case 1 (a) demonstrating approximately 38-40 expansion repeats 
whilst cases 2 (b) and 3 (c) showed around 20 repeats. C9orf72 sizing PCR (d and e): A normal 
control (d) with 2 and 8 repeats whilst Case 1 (e) demonstrated approximately 20-40 repeats. Note 
the constant non-specific peak at ~275 bp in both PCRs. The relative fluorescent unit y-axis scale has 
been zoomed-in to show the low-level peaks relating to the approximately 20-40 repeats in case 1. 
Southern blot analysis of Case 1 (f). Frontal cortex (lane 1) and cerebellum (lane 2) were analysed 
using Southern blot analysis to size the C9orf72 expansion repeat length. The results were compared 
to a blood sample from a C9orf72 positive case (lane 3) and a known negative control (lane 4). 
Pathological findings in Case 1 (g-t). p62 positive neuronal intranuclear inclusions (g) and neuronal 
cytoplasmic inclusions (h) were found in the cerebellum. Star-like neuronal cytoplasmic inclusions 
were found in the CA4 subregion of the hippocampus (i and j). The p62 positive star-like inclusions 
were also shown to contain the five DPRs; glycine-alanine (k), glycine-proline (l), and glycine-arginine 
(m) in the sense frames, and alanine-proline (n), and proline-arginine (o) in the anti-sense frames. 
Neuronal sense and anti-sense RNA foci were evident in the frontal cortex of Case 1. RNA 
fluorescent in-situ hybridisation for sense (red p-q) or anti-sense (green r-s) foci were combined with 
immunostaining for neurons with NeuN (green (q) or red (s)) and nuclear DNA staining with DAPI 
(blue). Quantification of the percentage of neurons containing sense or anti-sense RNA foci from 
RNA FISH in the frontal cortex (t). Scale bar in a represents 10µm in b-c and e-j  and 50µm in d. In k-n 
scale bar represents 2 μm.  
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